retatrutide nasal spray These highlights do not include all the information needed to use RYALTRIS® Retatrutide Nasal Spray | Reta

Its dual GLP-1 and GIP receptor activation produced a 20.9% average body weight reduction at 72 weeks in the SURMOUNT-1 trial, and more recent SURMOUNT-5 head-to-head data confirmed its superiority over Semaglutide

These areas have enough fat tissue, making them ideal for subcutaneous injections, ensuring that the medication is absorbed slowly and evenly into your bloodstream

Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists Use in Elderly People With Obesity A Meta-Analysis

Finally, maintain realistic expectations

For 95% of people: don't wait

For those using Semaglutide GLP-1 for diabetes management , improvements in glucose control may appear within days, while weight management benefits generally become more noticeable over several weeks